To meet the next "golden decade" of biomedicine, four short boards need to be supplemented

[market analysis of pharmaceutical network] bio medicine is connected with national planning and people's livelihood, and has become a key high-tech industry in the world China is also studying to build the biomedical industry into a new engine of high-quality economic development, gathering industrial resources and innovative elements, and all regions are actively responding to the development of biomedical industry Medicine (picture source: pharmaceutical network) For example, recently, Suzhou biomedical industry development plan (2018-2022) was released The plan has formulated a feasible development path around the industrial development focus, aiming to build Suzhou into an important biomedical innovation and development base in the world, a world-famous biomedical enterprise cluster, and a biomedical industry development core area with good domestic environment The plan puts forward the "1911" thinking of the development of Suzhou biomedical industry: to build a system: relying on the top ten biomedical industrial parks, to build a "Trinity" complete biomedical industry system of industrial cluster, technological innovation and factor guarantee Nine ways to promote: solid promotion to complete the industrial chain, local application demonstration, cultivation of key enterprises, optimization of talent structure, improvement of platform construction, promotion of collaborative innovation, expansion of financial support, innovation of regulatory system and innovation of development mode 11 tasks were implemented: cultivating local leading enterprises, improving clinical trial capacity, developing productive service industry, building medical image center, popularizing technology application center, building comprehensive talent echelon, improving three public platforms, creating innovation environment, enriching financial fund support, striving for policy first trial and building "1 + n" development mode In addition, Nanjing's biomedical industry has also made major breakthroughs For example, in 2018, the scale of Nanjing's biomedical industry reached 60 billion yuan There are 69 industrial enterprises on the scale of medicine, 26 industrial enterprises on the scale of medical devices, more than 800 biomedical R & D enterprises, more than 100 pharmaceutical wholesale enterprises, 2 National Top 100 pharmaceutical enterprises, and 8 enterprises with sales exceeding 1 billion yuan The city has formed an industrial cluster area of "one valley, one town and three parks" for biomedical industry, namely Nanjing biomedical Valley (Jiangbei new area), Nanjing life science and Technology Town (Jiangning District), Jiangsu life science and Technology Innovation Park (Qixia District), Gaochun medical and Health Industrial Park, Nanjing API Industrial Park (Jiangbei new area), "one valley, one town, three parks" biomedical industry main business income accounts for more than 65% of the city's biomedical In recent years, China has introduced a series of new measures from the aspects of strategic deployment, policy measures, specific planning, etc the rapid improvement of biomedical innovation capacity, continuous expansion of industrial scale, and continuous improvement of industrial environment have become a strategic emerging industry supported by the state Since 2018, under the pressure of the national 4 + 7 and other policies, the pharmaceutical industry is undergoing in-depth adjustment, especially with the volume purchase, the first, difficult and improved new drugs as well as the breakthrough in technology will continue to be favored by the market However, some experts pointed out that the development of new drugs is an interconnected ecosystem In the process of transformation from a big country of generic drugs to a powerful country of innovative drugs, there are four short boards that need to be supplemented Basic research Some industries believe that basic research is the source of new drug development In order to become a powerful country of innovative drugs, we must lay a solid foundation for basic research Both universities, scientific research institutions and new drug development enterprises should attach great importance to basic research, increase investment and deepen cooperation with greater efforts and an open mind, and strive to make breakthroughs in new discoveries, new targets and new technologies Clinical research For a long time, China has been dominated by generic drugs, and the clinical research of new drug development is still relatively weak Although in recent years, relevant departments and major hospitals have accelerated the construction of clinical research centers, but the quantity and quality need to be improved Low level repetitive R & D The industry pointed out that although the innovation speed of China's Biopharmaceutics has been significantly accelerated in recent years, the quality of innovation is not high, and the low-level duplication of "cluster innovation" is particularly prominent In this regard, no matter the State Administration or the investors or the heads of enterprises, we must attach great importance to it Regulatory policy The industry points out that if China's new drug research and development wants to make a breakthrough in the next decade, it cannot do without fair and just administrative supervision, and the continuity, scientificity, compliance and internationalization of policies are crucial China's pharmaceutical industry is still in the development state of small scale, scattered enterprises, insufficient innovation and low added value How to master the distribution of new global biomedical industry innovation resources, realize the global link of innovation elements, help enterprises in the park to improve innovation efficiency and reduce innovation cost is an urgent problem to be solved In order to better promote the development of biomedical industry, the above-mentioned short board problems also need to be supplemented According to the industry, the late train of pharmaceutical research and development in China has entered the fast lane and has a bright future With the joint efforts of all parties concerned, the next "golden decade" can be expected.